Privium Fund Management B.V. Sells 30,562 Shares of Zai Lab Limited (NASDAQ:ZLAB)

Privium Fund Management B.V. reduced its position in Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 14.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 185,062 shares of the company's stock after selling 30,562 shares during the period. Zai Lab accounts for approximately 1.1% of Privium Fund Management B.V.'s portfolio, making the stock its 20th largest holding. Privium Fund Management B.V. owned approximately 0.17% of Zai Lab worth $4,847,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ZLAB. China Universal Asset Management Co. Ltd. raised its stake in Zai Lab by 15.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,061 shares of the company's stock valued at $290,000 after purchasing an additional 1,502 shares in the last quarter. M&T Bank Corp raised its stake in shares of Zai Lab by 9.6% in the third quarter. M&T Bank Corp now owns 25,188 shares of the company's stock worth $608,000 after purchasing an additional 2,209 shares during the last quarter. XTX Topco Ltd lifted its position in Zai Lab by 8.0% during the third quarter. XTX Topco Ltd now owns 31,618 shares of the company's stock valued at $763,000 after purchasing an additional 2,335 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Zai Lab by 3.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 121,084 shares of the company's stock valued at $2,923,000 after purchasing an additional 3,860 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its holdings in Zai Lab by 44.7% in the 4th quarter. Daiwa Securities Group Inc. now owns 13,833 shares of the company's stock worth $362,000 after purchasing an additional 4,276 shares during the period. 41.65% of the stock is owned by institutional investors.

Remove Ads

Insider Transactions at Zai Lab

In other news, insider Rafael Amado sold 3,000 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $38.41, for a total value of $115,230.00. Following the completion of the sale, the insider now owns 30,834 shares in the company, valued at $1,184,333.94. This represents a 8.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Ying Du sold 50,000 shares of the company's stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the completion of the transaction, the chief executive officer now owns 494,117 shares in the company, valued at approximately $17,032,212.99. This represents a 9.19 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 125,127 shares of company stock worth $4,139,672. 13.88% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Scotiabank started coverage on shares of Zai Lab in a research note on Friday, March 7th. They set a "sector outperform" rating and a $55.00 target price for the company. JPMorgan Chase & Co. increased their price objective on Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, March 13th. Bank of America reaffirmed a "neutral" rating and issued a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Finally, Cantor Fitzgerald upgraded shares of Zai Lab to a "strong-buy" rating in a report on Tuesday, March 4th.

Zai Lab Stock Performance

ZLAB stock traded down $2.24 during midday trading on Friday, reaching $35.09. 1,109,977 shares of the company were exchanged, compared to its average volume of 751,561. The company has a market cap of $3.85 billion, a price-to-earnings ratio of -12.67 and a beta of 1.08. Zai Lab Limited has a 1-year low of $13.48 and a 1-year high of $39.61. The stock's 50-day simple moving average is $30.70 and its 200 day simple moving average is $27.75.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The company had revenue of $109.07 million during the quarter, compared to analysts' expectations of $110.15 million. On average, research analysts anticipate that Zai Lab Limited will post -2.58 earnings per share for the current year.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.